ESR1 and breast carcinoma: Our findings that there is a common requirement for the proteasome and HIF-1α in ER-α repression in hypoxic environments, among many different breast cancer genomes implies that ubiquitin ligase or proteasome inhibitors might be widely used in the clinic to potentiate the effects of hormonal therapies or delay/prevent therapeutic resistance.